Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Lifirafenib (BGB-283)(一种 RAF 家族激酶抑制剂)治疗实体瘤患者的 I 期开放标签剂量递增/剂量扩展研究
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.19.02654
Desai, Jayesh; Gan, Hui; Barrow, Catherine; Jameson, Michael; Atkinson, Victoria; Haydon, Andrew; Millward, Michael; Begbie, Stephen; Brown, Michael; Markman, Ben; Patterson, William; Hill, Andrew; Horvath, Lisa; Nagrial, Adnan; Richardson, Gary; Jackson, Christopher; Friedlander, Michael; Parente, Phillip; Tran, Ben; Wang, Lai; Chen, Yunxin; Tang, Zhiyu; Huang, Wendy; Wu, John; Zeng, Dewan; Luo, Lusong; Solomon, Benjamin